Canada markets close in 5 hours 36 minutes
  • S&P/TSX

    20,050.11
    +58.23 (+0.29%)
     
  • S&P 500

    4,233.86
    +26.59 (+0.63%)
     
  • DOW

    33,453.65
    +116.98 (+0.35%)
     
  • CAD/USD

    0.7815
    -0.0021 (-0.27%)
     
  • CRUDE OIL

    91.50
    -2.84 (-3.01%)
     
  • BTC-CAD

    30,514.22
    -1,337.62 (-4.20%)
     
  • CMC Crypto 200

    566.92
    -4.36 (-0.76%)
     
  • GOLD FUTURES

    1,810.20
    +3.00 (+0.17%)
     
  • RUSSELL 2000

    1,986.17
    +10.91 (+0.55%)
     
  • 10-Yr Bond

    2.8550
    -0.0330 (-1.14%)
     
  • NASDAQ

    12,904.39
    +124.47 (+0.97%)
     
  • VOLATILITY

    19.81
    -0.39 (-1.93%)
     
  • FTSE

    7,489.51
    +23.60 (+0.32%)
     
  • NIKKEI 225

    28,546.98
    +727.65 (+2.62%)
     
  • CAD/EUR

    0.7612
    +0.0024 (+0.32%)
     

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., June 03, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs were granted on May 31, 2022, vest as to one-quarter of the shares on May 31, 2023 and as to an additional one quarter of the shares at the end of each successive year thereafter subject to the employee’s continued service with Syros, and are subject to the terms and conditions of a restricted stock unit agreement covering the award and Syros’ 2022 Inducement Stock Incentive Plan.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005019/en/

Contacts

Media Contact
Courtney Solberg
Syros Pharmaceuticals
917-698-9253
csolberg@syros.com

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting